Exquisite Timing, page-16

Credit Suisse has more that $1 Billion at risk over its exposure to Greensill Capital. The bank has reportedly suspended the funds' managers and changed the head of its asset management unit.

In this environment, it is quite possible that the new leadership has directed staff to sell everything considered speculative, and this would include Noxopharm. Dumping more than 8 million shares in a short period has inevitably hurt the share price.

Happily, we simultaneously learnt that one patent is about to be granted in Europe, and a second is looking good in the US. It appears to me that the selling is unconnected to Noxopharm's future and that the SP will rebound once it stops.